JPS6169725A - Antitumor substance of spf-140 and its preparation - Google Patents
Antitumor substance of spf-140 and its preparationInfo
- Publication number
- JPS6169725A JPS6169725A JP59190560A JP19056084A JPS6169725A JP S6169725 A JPS6169725 A JP S6169725A JP 59190560 A JP59190560 A JP 59190560A JP 19056084 A JP19056084 A JP 19056084A JP S6169725 A JPS6169725 A JP S6169725A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- reaction
- spf
- antitumor
- antitumor substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、#r規な抗腫瘍性物質SPF−140及びそ
の製法に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to #r antitumor substance SPF-140 and its production method.
従来、溶血性連鎖状球菌(以下溶連菌という)の生菌体
を弱毒化して製剤化したものは、ナでに制癌剤として使
用されている〜
また、#溶菌の菌体を破砕抜水または塩類溶液で有効成
分を抽出し、有機温媒を加えて、抗腫瘍性物質を沈澱と
して、回収する方法(特公昭68−1647 )、m遍
園を溶菌酵素リゾチーム、セルラーゼまたは蛋白質分解
酵素により、#菌し、活性画分を水溶性区分として分画
する方法(英国特許第1163865号)、溶連−の菌
体を破砕抜水不溶性物質を採取し、核酸分解酵素および
蛋白分解酵素で処理する方法(特開昭55−7014)
などが知られている。Conventionally, preparations prepared by attenuating viable cells of hemolytic streptococcus (hereinafter referred to as ``hemolytic streptococci'') have been used as anticancer drugs. A method of extracting the active ingredients with organic hot medium, adding an organic heating medium, and recovering the antitumor substance as a precipitate (Special Publication No. 68-1647). A method of fractionating the active fraction as a water-soluble fraction (British Patent No. 1163865), a method of crushing the cells of Hemorrhoids, collecting water-insoluble substances, and treating them with nucleolytic enzymes and proteolytic enzymes ( Japanese Patent Application Publication No. 55-7014)
etc. are known.
このように、ストレプトコッカス属細菌そのものもしく
はその菌体成分に抗MljG活性があることは広く知ら
れているのであるが、従来仰られたものは、菌体もしく
は水溶性もしくは水不溶性高分子細胞構成吻貴であるに
過ぎなかった。歯体もしくは一体円から有効成分を単離
しよりとすれば、菌体を浴−シたり、機械的に破砕した
りして全体を分画しなければならなかった。As described above, it is widely known that Streptococcus bacteria themselves or their bacterial cell components have anti-MljG activity, but what has previously been said is that anti-MljG activity exists in bacterial cells or in water-soluble or water-insoluble polymer cell components. It was just noble. In order to isolate the active ingredient from the tooth bodies or integral circles, the entire bacterial body had to be fractionated by bathing or mechanically crushing it.
このような処理では、精製は複雑となり、有効成分の単
離はきわめて困難でめった。実際に分離し、+!−効成
分成分て測定された例では分子量200.000の蛋白
質が知られている(+!j公昭48−45841.・侍
開昭51−44617)に過ぎないつ本発明者らは、先
にストレプトコッカス属細菌の生産する抗凍瘍性有効成
分を求めて研究した結果、ストレプトコッカス属細菌の
培養の適切な生育期に、ベニ/リンまたはその関連物質
を少加し、更に培養を継続することによって、培地中に
分泌される生理活性物質5PF−1および5pp−2゜
抗腫瘍性物質5pp−i ooを培fP液中から回収し
、梢襄を行ない、虜規物質として採取した。Such treatments complicate purification and isolation of the active ingredient is extremely difficult and rare. Actually separate, +! - In the case of active ingredients measured, a protein with a molecular weight of 200,000 is known (+! As a result of research in search of anti-freezing active ingredients produced by bacteria of the genus Streptococcus, it was found that by adding a small amount of beni/phosphorus or related substances during the appropriate growth period of the culture of bacteria of the genus Streptococcus and continuing the culture. Physiologically active substances 5PF-1 and 5pp-2° and antitumor substances 5pp-ioo secreted into the culture medium were recovered from the culture fP solution, sieved, and collected as control substances.
これらの物質は、高分子透過性大腸菌変異株MP−2(
FjjRM−P5432 ) (Agr、 Birol
。These substances were obtained from the polymer-permeable E. coli mutant strain MP-2 (
FjjRM-P5432) (Agr, Birol
.
Chem、46,371〜57B(1979))(以ド
MP−2株という)に対して生育阻止能を有していた。Chem, 46, 371-57B (1979)) (hereinafter referred to as MP-2 strain).
本発明者らは、ストレプトコッカスf4細菌のこの培養
P液中に、8PPl、5PF−2或いは。In this culture P solution of Streptococcus f4 bacteria, we present 8PPl, 5PF-2 or.
SPFl 00とは別個に、MP−2株に対して生育阻
止作用を示さないが、抗@瘍活性を有する両分の存在す
ることを見出すく至ったのである。They have discovered that, apart from SPFl 00, there are two components that do not exhibit a growth-inhibitory effect on the MP-2 strain, but have anti-tumor activity.
本画分の物質は、SPF’−140と呼称する。The substance of this fraction is designated as SPF'-140.
本発明の抗腫瘍性物質SPF−140は、培養P液中に
分泌され、分子量が25.000〜70,000であり
、MP−2株に対する抗菌活性を示さないことによって
特徴ずけられる。The antitumor substance SPF-140 of the present invention is secreted into the culture P fluid, has a molecular weight of 25,000 to 70,000, and is characterized by not exhibiting antibacterial activity against MP-2 strain.
現在までに、溶連菌PA遵の抗腫瘍性物質で、培養液中
に分泌、蓄積され、分子量数万以下のものは知られてお
らず、更に、本発明の抗腫瘍性物質SPF−140は1
元素分析、呈色反応等からペプチド様物質と考えられる
が、紫外線吸収スペクトルから、既矧の抗腫瘍性物質と
は、相異する新規な物質と認められるものである。To date, there are no known antitumor substances related to streptococcus PA that are secreted and accumulated in the culture medium and have a molecular weight of less than several tens of thousands.Furthermore, the antitumor substance SPF-140 of the present invention
Although it is considered to be a peptide-like substance based on elemental analysis and color reaction, the ultraviolet absorption spectrum indicates that it is a new substance that is different from known anti-tumor substances.
本発明は、ストレプトコッカス属に属する抗騰瘍性物質
5PF−140生産菌を培養し、培養物から抗腫瘍性物
質SPF−140を採取することを特徴とする抗腫瘍性
物質5PF−140の製造法を色合するものである。The present invention provides a method for producing an antitumor substance 5PF-140, which comprises culturing an antitumor substance 5PF-140-producing bacterium belonging to the genus Streptococcus and collecting the antitumor substance SPF-140 from the culture. It is a color that matches the color of the color.
本発明においては、ストレゾトコツカス属に属する抗腫
瘍性物質SPF−140生産菌が広く使用できる、次に
抗腫瘍性物質5PF−140生産菌をd己滅する。In the present invention, bacteria producing the antitumor substance SPF-140 belonging to the genus Strezotococcus can be widely used, and then the bacteria producing the antitumor substance 5PF-140 are self-killed.
5treptococcus pyogenes A
TCC21060Streptococcus sp、
ATCC21597Streptococcu
s pyogenes ATCC215468tre
ptococcus pyogenes ATCC2
1547Streptococcus pyogene
s ATCC2154B培養液は、肉エキス培地、酵
母エキス培地、プレイン・ハート・イノフユージョy培
地(B Hr培地)等の天然培地がよく用いられるが、
ストレプトコッカス属細菌の生背に適した培地であれば
任意の培地を使用できる。5treptococcus pyogenes A
TCC21060Streptococcus sp,
ATCC21597Streptococcu
s pyogenes ATCC215468tre
ptococcus pyogenes ATCC2
1547Streptococcus pyogene
Natural media such as meat extract medium, yeast extract medium, plain heart infujoy medium (B Hr medium) are often used as ATCC2154B culture medium.
Any medium can be used as long as it is suitable for the growth of Streptococcus bacteria.
培養は、pi−15,o〜8.0.好ましくは、6.1
〜Z2であり、培1!温度は、30〜40’C,好まし
くは、65〜37℃であり、嫌気的に#置培養または、
撹拌培養を行なうことができる。Culture was carried out on pi-15,o~8.0. Preferably 6.1
~Z2 and cultivation 1! The temperature is 30 to 40°C, preferably 65 to 37°C, and the culture is carried out anaerobically or
Stirring culture can be performed.
本発明においては、培養中に適当な時期に、×ニジリン
または、その関連物質を添/I口することが、抗腫瘍性
物質SPF−140の採取に重要な役割をはだすことに
なる。In the present invention, adding/injecting xnigilin or its related substances at an appropriate time during culture plays an important role in collecting the antitumor substance SPF-140.
はニジリンまたは、その関連物質の添加時間は。is the addition time of Nijirin or its related substances.
67℃の培養で、対数増殖期にかかつて後、6〜20時
間の間、特に5〜10時間が好ましい。その後1〜20
時間、好ましくは、3〜15時間培養を継続することに
よシ、培養中に抗腫瘍性物質SPF−140を多量蓄積
させることができる。Cultivation at 67° C. is preferably carried out for 6 to 20 hours, particularly 5 to 10 hours, after reaching the logarithmic growth phase. Then 1-20
By continuing the culture for a period of time, preferably 3 to 15 hours, a large amount of the antitumor substance SPF-140 can be accumulated during the culture.
ペニシリンまたはその関連物質としては、すでに知られ
た−”? ニシリ/と類似の活用をもつ関連物質であれ
ばいかなるものでもよいが、ペニシリンGが普通用いら
れる。添加竜は、ペニシリンGで100〜7000単位
/d、好ましくは、500〜5000単位/4培養液程
度で十分である。As penicillin or its related substances, any related substance that has a similar use to the already known -"? nishiri/ can be used, but penicillin G is usually used. About 7000 units/d, preferably 500 to 5000 units/4 culture solution, is sufficient.
ストンブトコツカス属細菌のはニジリンまたは、その関
連物質の添加培養によって得られた培養液は、遠心分離
によって画体を除去し、戸液に硫安を添加し、50〜9
CJ%飽和度の画分を分取する。A culture solution obtained by adding Nijirin or its related substances to bacteria belonging to the genus Stombutococcus is centrifuged to remove the medium, and ammonium sulfate is added to the solution.
Fractions with CJ% saturation are collected.
得られだ抗腫瘍性物質5PF−140を含む硫安塩析物
は、凍結状態で保存することもできる。The obtained ammonium sulfate precipitate containing the antitumor substance 5PF-140 can also be stored in a frozen state.
この硫安塩析物から抗腫瘍性物質!IIIPF−140
を抽出するには、塩析物を緩衝液に溶解し、イオン交換
体を用いて回分法または流通法により吸着および浴出を
行ない、更にケ゛ル濾過剤を用いるクロマトグラフィー
により、抗腫瘍性物質SPF’−140を分画する。This ammonium sulfate precipitate is an antitumor substance! IIIPF-140
To extract the antitumor substance SPF, the salt precipitate is dissolved in a buffer solution, adsorbed and washed out using an ion exchanger using a batch method or a flow method, and further chromatography using a gel filtration agent. '-140 is fractionated.
イオン交換体としては、イオン交換樹脂、イオン交換セ
ルロース、イオン交換セファデックス(ファルマシア社
fi)、ハイトロキシルアパタイト等が用いられ、ケ゛
ルp過剤としては、トヨパールHW50F’lたはHW
50 S F (東洋q達(株)製)。As the ion exchanger, ion exchange resin, ion exchange cellulose, ion exchange Sephadex (Pharmacia fi), hydroxylapatite, etc. are used, and as the cell purifying agent, Toyopearl HW50F'l or HW
50 SF (manufactured by Toyo Qtatsu Co., Ltd.).
セファデックス(ファルマシア社製)等が用いられる。Sephadex (manufactured by Pharmacia) or the like is used.
イオン交換体への抗腫瘍性物質SPF−140の吸着お
よびイオン交換体からの抗腫瘍性物質5PF−140の
溶出は、適切な−と塩濃度の緩衝液が用いられる。更に
、イオン交換体およびゲル濾過剤は2種類以上を組合せ
て用いることもできる。A buffer solution with an appropriate salt concentration is used for adsorption of the antitumor substance SPF-140 to the ion exchanger and elution of the antitumor substance 5PF-140 from the ion exchanger. Furthermore, two or more types of ion exchangers and gel filtration agents can be used in combination.
実施例1で得られた抗腫瘍性物質SPF−140の凍結
乾燥標品は、淡黄色の粉末であり、次のような理化学的
性質を示すう
1、元素分析
C:42.58%〜41.79%
H: 6.15%〜 5,92チ
N:12.69%〜12.55%
2、分子量
ゲル濾過法による測定では、分子量約
25.000〜70.000である。The freeze-dried specimen of the antitumor substance SPF-140 obtained in Example 1 is a pale yellow powder, and exhibits the following physical and chemical properties: Elemental analysis C: 42.58% to 41 .79% H: 6.15% to 5,92% N: 12.69% to 12.55% 2. Molecular weight As measured by gel filtration, the molecular weight is about 25.000 to 70.000.
五 分解点
本物質は170℃で褐変し、245℃になると黒色とな
り分解する。5. Decomposition point This substance turns brown at 170℃ and turns black at 245℃ and decomposes.
4、比旋光度
(a)%’=−70.0°〜−80,0°(C=1.0
O)5、紫外線吸収スペクトル
本物質の0.1%の水浴液の紫外線吸収スペクトルは第
1図に示される。275nmに吸収極大がみられ特徴的
である。4. Specific rotation (a) %' = -70.0° to -80.0° (C = 1.0
O) 5. Ultraviolet Absorption Spectrum The ultraviolet absorption spectrum of a 0.1% water bath solution of this substance is shown in FIG. The absorption maximum is observed at 275 nm, which is characteristic.
6. 赤外巌吸収スにクトル 渠2図に示される。6. Infrared absorption filter The culvert is shown in Figure 2.
Z 浴剤に対する溶解性
水に口fmであるが、メタノールには一部溶解シ、エタ
ノール、n−foA/−A/。Z Solubility of bath additives: fm in water, but partially soluble in methanol, ethanol, n-foA/-A/.
n−ブタノール、イノブタノール、n−ヘキサン、クロ
ロホルム、アセトン、メチルイソブチルケトン、エチル
エーテル等の溶剤には謔溶又は不溶である。It is soluble or insoluble in solvents such as n-butanol, inobutanol, n-hexane, chloroform, acetone, methyl isobutyl ketone, and ethyl ether.
8、塩基性、酸性、中性の区別 本物質の1.0チ水溶液の…は6.5である。8. Distinction between basic, acidic, and neutral ... of a 1.0% aqueous solution of this substance is 6.5.
9 物質の色 淡黄色粉末状である。9 Color of matter It is a pale yellow powder.
io、 呈色反応 二/ヒドリン反応 十 ビュウレット反応 十 ローリ−反応 十 そ−リッシュ反応 − デイシエ反応 − アンスロン反応 − システィン硫酸反応 − 11、安定化 本物質は特に安定化剤を必要としない。io, color reaction 2/Hydrin reaction 10 Buret reaction 10 Lowry reaction 10 Solish reaction Deissier reaction - Anthrone reaction − Cystine sulfuric acid reaction - 11. Stabilization This substance does not require any special stabilizers.
次に本発明における抗菌活性は次の様にして測定する。Next, the antibacterial activity in the present invention is measured as follows.
抗菌活性
測定にはMP−2を使用して、MP−2に対する生育阻
止能をもって抗菌活性の指標とする。また、この原理を
利用し九鵜高法(J、 Antibiotics。MP-2 is used to measure antibacterial activity, and the ability to inhibit the growth of MP-2 is used as an indicator of antibacterial activity. Also, utilizing this principle, the Kuu Taka method (J, Antibiotics.
35.1319〜1325(1982))にょシ、生理
活性物質の単位を決定する。35.1319-1325 (1982)) Determination of units of physiologically active substances.
すなわち、バクト・アンチバイオチックメディアム5(
ディ7コ社mlり1.75%、 寒天1.51よシ成る
培1(M5培地)を1200.15分加熱殺菌し、20
114ずつシャーレに分注し、放冷してプレート培地を
fJ!4襄する。That is, Bacto Antibiotic Medium 5 (
Culture medium 1 (M5 medium) consisting of Di7co Co., Ltd. 1.75% agar and 1.51 ml was heat sterilized for 1200.15 minutes, and
Dispense 114 cells into petri dishes, let it cool, and use the plate medium as fJ! Make 4 bowls.
一方、イブ1−70.5優、肉エキスα5%、塩化ナト
リウム0.5慢、寒天α8チより成る培地を120℃、
15分加熱殺菌する。その後42℃の恒温槽に保ち、培
地の温度が42℃になったらあらかじめ57℃で17時
間培養し九MP−2Mをi 、717中に10JI61
の細胞が存在するように培地中に加えるうピペットによ
って21Llを採取し、あらかじめ作製して置いたM6
6培地面上に7JOえ、すばやく均一にひろげ固化させ
る。次いで被験液を適当に希釈して、その溶液0.05
a/l−<−パー・ディスク(直径8属鳳)(東洋P紙
(株1!りKLみ込ませる。このペーパー・ディスクを
前記作製プレート上に置き、57℃で17時間培養し、
被験物質によってできる阻止円の観察して抗菌活性を検
査し、阻と円の直径101111を与える被験物質の生
理活性を測定し、一単位(1u)と定義する。On the other hand, a medium consisting of Eve 1-70.5%, meat extract α5%, sodium chloride 0.5%, and agar α8% was heated at 120°C.
Sterilize by heating for 15 minutes. After that, it was kept in a constant temperature bath at 42°C, and when the temperature of the medium reached 42°C, it was incubated at 57°C for 17 hours, and 9MP-2M was incubated with 10JI61 in 717.
Collect 21Ll with a pipette and add it to the culture medium so that there are M6 cells prepared in advance.
6. Spread 7JO on the surface of the medium and spread quickly and uniformly to solidify. Next, the test solution was diluted appropriately, and the solution was 0.05
a/l-<-par disk (diameter 8 genera) (Toyo P Paper Co., Ltd. 1!Imbued with KL. This paper disk was placed on the above-mentioned preparation plate and cultured at 57°C for 17 hours.
The antibacterial activity is tested by observing the inhibition circle formed by the test substance, and the physiological activity of the test substance that gives a diameter of 101111 mm is defined as one unit (1 u).
次に本発明の実施例を示す。Next, examples of the present invention will be shown.
々ttt*f!/す1
Streptococcus pyogenes AT
CC2−1060をBHI培地100dに接種して37
℃、8時間静置培aをおこなって侍た柿培養液を第1表
に示す培地A1 gK接棟し、種培養と同一条件で嫌気
的に前培養を行った。ttt*f! /su1 Streptococcus pyogenes AT
CC2-1060 was inoculated into 100 d of BHI medium and 37
The persimmon culture solution that had been incubated for 8 hours at ℃ was added to the medium A1 gK shown in Table 1, and precultured anaerobically under the same conditions as the seed culture.
第1 表 培地人
肉エキス 1.0チ
ポリはプトン 1. Oチマルトース
α5%
酵母エキス Q、25チ酸性第−燐酸カ
リウム α1チ
[11!−’rグネシウA 0.05*…
=6.8
101ジャーファーメンタ−に培地A81を投入して1
20℃、10分間加熱殺菌後、57℃まで冷却して、前
培養液11を接種し、37℃、15.5時間、…6.5
,300回転/分で撹拌しながら嫌気的に培養する。次
いでペニシリンG5000単位/d培養液になるように
添加して、培養を更に5時間継続した。得られた培養液
を遠心分離にかけて、菌体を除去した。Table 1 Cultured Human Flesh Extract 1.0 Chipori is Pton 1. O thymaltose
α5% Yeast extract Q, 25 thionic potassium phosphate α1 thi [11! -'r Gnesiu A 0.05*...
=6.8 Pour medium A81 into 101 jar fermenter and add 1
After heat sterilization at 20°C for 10 minutes, cooled to 57°C, inoculated with preculture solution 11, heated at 37°C for 15.5 hours...6.5
, anaerobically cultured with stirring at 300 revolutions/min. Then, penicillin G was added at 5000 units/d culture solution, and the culture was continued for an additional 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養F液には硫酸アンモニウムを添加し、50〜90チ
飽和度で沈澱する画分を分取した。この沈澱物はMP−
2の生育を阻止する生理活性物質381、 OX 10
’ uを含有していた。、この沈澱物を、lX10−2
M、pa−17:0の燐酸緩衝液O伍ぼ04− Na1
HPO4)300111に溶解し、この水溶液をDB人
Eセルローズカラム(5x70cIIL)に吸着させた
後、α3M塩化ナトリウムを含む上記燐酸緩衝液を用い
て、段階的に溶出させ、283.4x10’Uの生理活
性画分を分取した。この生理活性画分をDBAI!fセ
ファデックス人−25カラム(2,6×70(、IIL
)に吸着させ、次いで上記燐酸緩衝液中の塩化ナトリウ
ム濃度を直線的に上昇させて溶出を行ない、249.6
X 10’ uの生理活性区分を分取した。更に、こ
の溶出液を濃縮し、ゲルー過剤トヨパールHW50Fカ
ラム(2,6X 100cm)に加えて、ゲル濾過を行
ない、非抗菌活性画分を分取して、凍結乾燥し抗腫瘍性
物質5PF−140640=9を得た。Ammonium sulfate was added to culture solution F, and a fraction precipitated at a saturation level of 50 to 90% was collected. This precipitate is MP-
381, a physiologically active substance that inhibits the growth of OX 10
' Contained u. , this precipitate was
M, pa-17:0 phosphate buffer O504-Na1
HPO4) 300111, and this aqueous solution was adsorbed on a DB Human E cellulose column (5x70cIIL), and then eluted stepwise using the above phosphate buffer containing α3M sodium chloride. The active fraction was collected. This physiologically active fraction is DBAI! f Sephadex - 25 columns (2,6 x 70 (, IIL
), and then elution was performed by linearly increasing the sodium chloride concentration in the phosphate buffer, and 249.6
A bioactive fraction of X 10' u was collected. Furthermore, this eluate was concentrated and added to a gel-filtration agent Toyopearl HW50F column (2.6X 100cm) to perform gel filtration, and the non-antibacterial active fraction was collected and freeze-dried to obtain the antitumor substance 5PF- 140640=9 was obtained.
この抗腫瘍性物質SPF−140を被験物質とした抗腫
瘍性物質は、実験例1および2に示す。Antitumor substances using this antitumor substance SPF-140 as a test substance are shown in Experimental Examples 1 and 2.
実権例2
Streptococcus pyogenes AT
CC21060を第2表に示す培地Bを用いて、実施例
1と同様にして培養した。この場合ベニ’/!JンG#
f、1000単位/Ml培養液となるように添加した。Actual example 2 Streptococcus pyogenes AT
CC21060 was cultured in the same manner as in Example 1 using medium B shown in Table 2. In this case Beni'/! J-G #
f, 1000 units/Ml culture solution was added.
この培養P液を実施例1と同様に精製して、抗腫瘍性物
質SPF−140767I9を得た。This culture P solution was purified in the same manner as in Example 1 to obtain the antitumor substance SPF-140767I9.
第2表 培地B
肉エキス 0.5チ
ポリはプトン 1. CI Ls酵母エキス
0.25チ
塩化ナトリウム 0.1%
pi(=6.7
実施例3
Streptococcus pyogenes AT
CC21060を第3表に示す培地Cを用いて、実施例
1と同様にして培養した。この培養F液を実施例1と同
様セして精製して、抗腫4性物質5PF140 527
雫を得た。Table 2 Medium B Meat Extract 0.5 Cipoly is Pton 1. CI Ls Yeast Extract 0.25 Ti Sodium Chloride 0.1% pi (=6.7 Example 3 Streptococcus pyogenes AT
CC21060 was cultured in the same manner as in Example 1 using medium C shown in Table 3. This culture solution F was purified in the same manner as in Example 1 to obtain an antitumor substance 5PF140 527.
I got a drop.
第6表 培地C
肉エキス 1.0%
ポリにプトン 1.0俤
マルトース 0.5 %
酵母エキス 0.25チ
酸性第−燐酸カリウム o、i*
イ流酸マグネ7ウム” α05チ項化ナトリウム
O,Sチ
m= 6.5
実施例4
8treptococcus pyogenes AT
CC21060を第4表に示す培地りを用いて、実施例
1と同様にして培養した。この1合、にニアリンGは、
1000単位/d培養となるように添加したっこの培養
(戸数を実施列1と同様にして精製して抗腫瘍性物質5
PF−140830ダを傅た。Table 6 Medium C Meat extract 1.0% Polynipton 1.0 t Maltose 0.5 % Yeast extract 0.25 thiopotassium phosphate o, i* Magnesium sulfate O, S temperature = 6.5 Example 4 8treptococcus pyogenes AT
CC21060 was cultured in the same manner as in Example 1 using the culture medium shown in Table 4. In this first go, nearing G is,
This culture was added to give 1000 units/day of culture (the number of cells was the same as in Example 1, and the antitumor substance was purified by 5
Passed PF-140830.
第4衣 培地D
マルトース 0.8%
ポリはプトン 0.1%
酵母エキス O,V%
酸性rルー燐酸カリウム 1.45慢硫埴マグネシウ
ム 0.585チ硝酸カリウム 1
. Oチ!利=6.5
実施例5
Streptococcus pyogenes AT
CC21060を第5表に示す培地Bを用いて、実施例
1と同様にして培養した。この場合、ハニシリンGは、
1000単位/d培讐液となるように添加した。この培
養P液を実施例1と同様にして精製して、抗腫瘍性物質
19PF−140570In9を得た。4th coating Medium D Maltose 0.8% Polypton 0.1% Yeast extract O, V% Acidic potassium phosphate 1.45 Chronic magnesium sulfate 0.585 Potassium nitrate 1
.. Ochi! Yield = 6.5 Example 5 Streptococcus pyogenes AT
CC21060 was cultured in the same manner as in Example 1 using medium B shown in Table 5. In this case, Hanicillin G is
The solution was added at a concentration of 1000 units/d of culture solution. This culture P solution was purified in the same manner as in Example 1 to obtain antitumor substance 19PF-140570In9.
第5表 培地E
マルトース α3%
カザミノ酸 0.5%
酵母エキス 1.0係
酸性第−燐酸カリウム 0.5%
gtrsマグネシウム 0.1%塩化ナトリウム
0.1%
硝酸カリウム 0.5%
m=6.5
実験例1
in vitro Icおける被検薬の抗腫瘍活性測定
試験は細胞阻害度測定法にもとづいて実施した。Table 5 Medium E Maltose α3% Casamino acids 0.5% Yeast extract 1.0 Acidic potassium phosphate 0.5% gtrs Magnesium 0.1% Sodium chloride 0.1% Potassium nitrate 0.5% m=6. 5 Experimental Example 1 An in vitro Ic test to measure the antitumor activity of the test drug was carried out based on the cell inhibition degree measurement method.
肺癌細胞としてはL −517B Y (Leukem
ia )を用い、これを10チFC8箔加RPMI 1
640培地(5、qry、/ lカナマイシン含有)に
懸濁した。L-517B Y (Leukem
ia), and added this to 10-inch FC8 foil RPMI 1
640 medium (containing 5,qry,/l kanamycin).
この培養液0.45mをファルコン2058チューブに
圧加し、細胞数がI X 105celjl / tu
be になるようにした。仄いてこの培養液に所定量
の被検薬(抗腫瘍性*質SPF’−140をQ、35m
/の培養液に溶解)を圧加して、57℃で5チω、存在
Fに培養した。彼検薬を添加して48時間後にトリノξ
ンブルーによる染色をおこない、次式により−d帖阻害
変を算出した。Pressurize 0.45 m of this culture solution into a Falcon 2058 tube until the number of cells reaches I x 105 celjl/tu.
I changed it to be. A predetermined amount of the test drug (anti-tumor* quality SPF'-140 was added to this culture solution at 35 m
/ dissolved in a culture solution) was pressurized and cultured at 57°C to 5°C. 48 hours after adding the test drug, Torino ξ
The staining was carried out with blue, and the -d block inhibition change was calculated using the following formula.
実mξ例1で得らまた抗腫瘍性物質SPF−140を被
検薬とした結果を!6表に示す。Results obtained in Example 1 using the antitumor substance SPF-140 as the test drug! It is shown in Table 6.
第 6 表 細胞阻害度■
SPF’−140(=n9/m/) L−5178
Y2.0 154
1.0 11.!1
実験例2
1幀voにおける被検薬の抗腫瘍活性試験はCRJ−C
D−1(ICR系、雌性、5週齢)マウスを1!2用し
て実施した。Table 6 Cell inhibition degree ■ SPF'-140 (=n9/m/) L-5178
Y2.0 154 1.0 11. ! 1 Experimental Example 2 The antitumor activity test of the test drug in 1 vo was CRJ-C.
The test was carried out using 1 to 2 D-1 (ICR strain, female, 5 weeks old) mice.
腫瘍細胞としてはSarcoma −180腹水癌細胞
を用い、これを生理食塩水に浮遊させ、マウスの腹腔内
K O,2m (細胞数I X 10’ cellls
)接種した。Sarcoma-180 ascites cancer cells were used as the tumor cells, suspended in physiological saline, and incubated intraperitoneally in mice at KO, 2 m (cell number I x 10' cells).
) inoculated.
この腫瘍細胞接種後、1日1回7日間遅続して被検薬の
所定量を腹腔内に投与して、その生存数を観察した。After the tumor cell inoculation, a predetermined amount of the test drug was administered intraperitoneally once a day for 7 days, and the number of survivors was observed.
実施例1で得られた抗腫瘍性物質SPF−140を被検
薬とした結果を第7表に示す。Table 7 shows the results using the antitumor substance SPF-140 obtained in Example 1 as the test drug.
第 7 表 SPF−140の抗腫瘍活性−マウスの
生存数
日 数
投与t(In9) 0 10 15 20
25 50対照 515 215 115 015
015 0150.3 515 515
515 4/〆5 4/コ 615ま
た、延命率=被検動物群の平均生存日数/対照動物群の
平均生存日数×100は270%であった。Table 7 Antitumor activity of SPF-140 - Days of survival of mice Number of administrations t(In9) 0 10 15 20
25 50 control 515 215 115 015
015 0150.3 515 515
515 4/〆5 4/ko 615 Furthermore, the survival rate = average survival days of test animal group/average survival days of control animal group x 100 was 270%.
81図は抗腫瘍性物’]SPF’−1400,1%水溶
液の紫外線吸収ス×クトルを示し、第2図は同じく赤外
線吸収スペクトルを示す。Figure 81 shows the ultraviolet absorption spectrum of a 1% aqueous solution of the antitumor substance 'SPF'-1400, and Figure 2 similarly shows the infrared absorption spectrum.
Claims (3)
−140。 1、元素分析 C:42.58%〜41.79%、 H:6.15%〜5.92%、 N:12.69%〜12.35% 2、分子量 ゲル濾過法による測定では、分子量約 25,000〜70,000である。 3、分解点 本物質は、170℃で褐変し、245 ℃になると黒色となり分解する。 4、比旋光度 〔α〕^2^0_D=−70.0°〜−80.0°(C
=1.00)5、紫外線吸収スペクトル 本物質の0.1%の水溶液の紫外線吸収 スペクトルは第1図に示される。 275 nmに吸収極大がみられ、特徴的であ る。 6、赤外線吸収スペクトル 第2図に示される。 7、溶剤に対する溶解性 水に可溶であるが、メタノールには一 部溶解し、エタノール、n−プロパノ ール、n−ブタノール、イソブタノー ル、n−ヘキサン、クロロホルム、ア セトン、メチルイソブチルケトン、エ チルエーテル等の溶剤には難溶又は不 溶である。 8、塩基性、酸性、中性の区別 本物質の1.0%水溶液のpHは6.5である。 9、物質の色 淡黄色粉末状である。 10、呈色反応 ニンヒドリン反応 + ビュウレット反応 + ローリー反応 + モーリッシュ反応 − デイシエ反応 − アンスロン反応 − システイン硫酸反応 − 11、安定化 本物質は、特に安定化剤を必要としな い。(1) SPF, an antitumor substance with the following physical and chemical properties
-140. 1. Elemental analysis C: 42.58% to 41.79%, H: 6.15% to 5.92%, N: 12.69% to 12.35% 2. Molecular weight As measured by gel filtration method, the molecular weight Approximately 25,000 to 70,000. 3. Decomposition point This substance turns brown at 170°C and turns black at 245°C and decomposes. 4. Specific rotation [α] ^2^0_D = -70.0° to -80.0° (C
=1.00) 5. Ultraviolet absorption spectrum The ultraviolet absorption spectrum of a 0.1% aqueous solution of this substance is shown in FIG. The absorption maximum is observed at 275 nm, which is characteristic. 6. Infrared absorption spectrum shown in Figure 2. 7. Solubility in solvents Soluble in water, but partially soluble in methanol, including ethanol, n-propanol, n-butanol, isobutanol, n-hexane, chloroform, acetone, methyl isobutyl ketone, ethyl ether, etc. It is sparingly soluble or insoluble in solvents. 8. Distinction between basic, acidic, and neutral The pH of a 1.0% aqueous solution of this substance is 6.5. 9. The color of the substance is pale yellow powder. 10. Color reaction Ninhydrin reaction + Buuret reaction + Lowry reaction + Molisch reaction - Decier reaction - Anthrone reaction - Cysteine sulfate reaction - 11. Stabilization This substance does not particularly require a stabilizer.
F−140生産菌を培養し、培養物から抗腫瘍性物質S
PF−140を採取することを特徴とする抗腫瘍性物質
SPF−140の製法。(2) Antitumor substance SP belonging to the genus Streptococcus
The F-140-producing bacteria were cultured, and the antitumor substance S was extracted from the culture.
A method for producing an antitumor substance SPF-140, which comprises collecting PF-140.
F−140生産菌を培養するに際し、培養中の適当な時
期にペニシリン又はその関連物質を添加して培養するこ
とを特徴とする特許請求の範囲第2項に記載の抗腫瘍性
物質SPF−140の製法。(3) Antitumor substance SP belonging to the genus Streptococcus
The antitumor substance SPF-140 according to claim 2, characterized in that when culturing the F-140 producing bacteria, penicillin or a related substance is added at an appropriate time during the culturing. manufacturing method.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59190560A JPS6169725A (en) | 1984-09-13 | 1984-09-13 | Antitumor substance of spf-140 and its preparation |
GB08522309A GB2164338B (en) | 1984-09-13 | 1985-09-09 | Tumoricidal substance spf-140 and process for the preparation thereof |
DE3532321A DE3532321C2 (en) | 1984-09-13 | 1985-09-11 | Tumoricidal substance SPF-140 and process for its preparation |
NL8502483A NL8502483A (en) | 1984-09-13 | 1985-09-11 | MEDICINAL PRODUCT SPF-140 WITH AN ACTION AGAINST TUMORS, AND METHOD FOR THE PREPARATION THEREOF. |
SE8504228A SE461222B (en) | 1984-09-13 | 1985-09-12 | TUMORATIVE SUBSTANCES SPF-140 AND PROCEDURES FOR PREPARING THEREOF |
FR8513603A FR2569983B1 (en) | 1984-09-13 | 1985-09-13 | TUMORICIDAL SUBSTANCE SPF-140 AND PROCESS FOR ITS PREPARATION |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59190560A JPS6169725A (en) | 1984-09-13 | 1984-09-13 | Antitumor substance of spf-140 and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6169725A true JPS6169725A (en) | 1986-04-10 |
JPH0156073B2 JPH0156073B2 (en) | 1989-11-28 |
Family
ID=16260095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59190560A Granted JPS6169725A (en) | 1984-09-13 | 1984-09-13 | Antitumor substance of spf-140 and its preparation |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPS6169725A (en) |
DE (1) | DE3532321C2 (en) |
FR (1) | FR2569983B1 (en) |
GB (1) | GB2164338B (en) |
NL (1) | NL8502483A (en) |
SE (1) | SE461222B (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS557014A (en) * | 1978-06-29 | 1980-01-18 | Chugai Pharmaceut Co Ltd | Antitumor agent and its preparation |
JPS5632492A (en) * | 1979-08-28 | 1981-04-01 | Mitsui Toatsu Chem Inc | Antitumor active substance, its preparation and pharmaceutical |
JPS58222026A (en) * | 1982-06-18 | 1983-12-23 | Masahiro Yoshimura | Anticancer substance |
JPS6092218A (en) * | 1983-10-26 | 1985-05-23 | Juzo Udaka | Production of antitumor substance |
EP0154549B1 (en) * | 1984-03-09 | 1990-12-27 | Kabushiki Kaisya Advance | Anticariogenic or antiperiodontitic agent |
-
1984
- 1984-09-13 JP JP59190560A patent/JPS6169725A/en active Granted
-
1985
- 1985-09-09 GB GB08522309A patent/GB2164338B/en not_active Expired
- 1985-09-11 DE DE3532321A patent/DE3532321C2/en not_active Expired - Fee Related
- 1985-09-11 NL NL8502483A patent/NL8502483A/en not_active Application Discontinuation
- 1985-09-12 SE SE8504228A patent/SE461222B/en not_active IP Right Cessation
- 1985-09-13 FR FR8513603A patent/FR2569983B1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DE3532321A1 (en) | 1986-03-27 |
GB2164338B (en) | 1988-05-05 |
FR2569983B1 (en) | 1988-08-19 |
GB8522309D0 (en) | 1985-10-16 |
GB2164338A (en) | 1986-03-19 |
JPH0156073B2 (en) | 1989-11-28 |
DE3532321C2 (en) | 1994-04-07 |
NL8502483A (en) | 1986-04-01 |
SE8504228D0 (en) | 1985-09-12 |
SE8504228L (en) | 1986-03-14 |
FR2569983A1 (en) | 1986-03-14 |
SE461222B (en) | 1990-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107137628B (en) | Hyaluronidase inhibitor derived from symbiotic fermentation product and application thereof | |
US4163780A (en) | Ks-2-a | |
DE2919132A1 (en) | SUBSTANCE KS-2-B, PROCESS FOR THEIR PRODUCTION AND MEANS CONTAINING THIS SUBSTANCE | |
US4209507A (en) | Novel anti-tumor substance and preparation thereof | |
JPS6169725A (en) | Antitumor substance of spf-140 and its preparation | |
US4656037A (en) | SPF-100 and process for the preparation thereof | |
DE2326916C2 (en) | Anhydro-4-carbamoyl-5-hydroxy-1-ribofuranosylimidazolium hydroxide | |
JPH0699314B2 (en) | Macrophage activator | |
DE3031152C2 (en) | ||
KR20230155271A (en) | Cosmetic composition containing hyaluronic acid for skin moisturizing , prepared using red ginseng polysaccharide | |
JPH08333214A (en) | Antiviral and antimicrobial agent | |
KR0183443B1 (en) | Preparation of antitumor and immunostimulating fraction from streptococcus agalactiae | |
JPH06183981A (en) | Antiulcer agent containing muco polysaccharide extracellularly produced by chlorella bacterium | |
CH583296A5 (en) | Bredinine - antiviral agent and immunosuppressant | |
JPS6216426A (en) | Antitumor component spf-10 and production thereof | |
JPH0155276B2 (en) | ||
JPS6030689A (en) | Physiologically active substance spf-1 and its preparation | |
JPH0156076B2 (en) | ||
JPS60104017A (en) | Antitumor agent | |
JPS63156707A (en) | Cosmetic containing hyaluronic acid | |
JPS60218323A (en) | Antitumor composition spf-100 and its preparation | |
JPH03184995A (en) | Antitumor agent | |
JPS62164629A (en) | Spf 10-12: antitumor component and its preparation | |
JPH0156075B2 (en) | ||
DE1203913B (en) | Process for the production of high molecular weight medicinal substances from non-pathogenic anaerobic cultures |